Table 1.
The characteristics of the included studies.
| Study | Country | Sample size (female/male) | Intervention | Relevant outcomes | Mean age (years) | Duration | |||
|---|---|---|---|---|---|---|---|---|---|
| Trial group | Control group | Trial group | Control group | Trial group | Control group | ||||
| Movahed et al. [23] | Iran | 33 (16/17) | 31 (17/16) | Resveratrol 500 mg, bid | Microcellulose (placebo) 500 mg, bid | HOMA-IR, HbA1c, fasting blood glucose, fasting insulin, TC, TG, HDL-C, LDL-C | 52.45 ± 6.18 | 51.81 ± 6.99 | 1.5 months |
| Goh et al. [24] | Singapore | 5 (0/5) | 5 (0/5) | Resveratrol 500 mg, qd, initially, increased by 500 mg per day every 3 days, to a maximum dose of 3000 mg per day (1000 mg, tid) | Placebo 500 mg, qd, initially, increased by 500 mg per day every 3 days, to a maximum dose of 3000 mg per day (1000 mg, tid) | HbA1c, fasting blood glucose, fasting insulin, TC, TG, HDL-C, LDL-C, adverse events | 55.8 ± 7.3 | 56.8 ± 5.3 | 3 months |
|
| |||||||||
| Brasnyó et al. [25] | Hungary | 10 (0/10) | 9 (0/9) | Resveratrol 5 mg, bid | Placebo, bid | HOMA-IR | 57.79 ± 7.9 | 52.5 ± 11.1 | 1 month |
|
| |||||||||
| Bashmakov et al. [26] | Egypt | 14 (6/8) | 10 (3/10) | Resveratrol 50 mg, bid | Placebo, bid | Fasting blood glucose, fasting insulin, TC, HDL-C, LDL-C | 54.0 ± 10.1 | 59.8 ± 6.6 | 2 months |
|
| |||||||||
| Bhatt et al. [27] | India | 28 (20/9) | 29 (16/12) | Resveratrol 250 mg, qd, with oral hypoglycemic agents such as glibenclamide and/or metformin | Oral hypoglycemic agents such as glibenclamide and/or metformin | HbA1c, fasting blood glucose, TC, TG, HDL-C, LDL-C | 56.67 ± 8.91 | 57.75 ± 8.71 | 3 months |
|
| |||||||||
| Zare Javid et al. [15] | Iran | 21 (18/4) | 22 (16/5) | Resveratrol 240 mg, bid | Starch (placebo) 240 mg, bid | HOMA-IR, fasting blood glucose, fasting insulin, TG | 49.1 ± 7.4 | 50.9 ± 8.9 | 1 month |
|
| |||||||||
| Bo et al. [16, 28, 29] | Italy | 130 (51/79) | 62 (15/47) | Resveratrol 500 mg, qd, or 40 mg, qd | Placebo, qd | HOMA-IR, HbA1c, fasting blood glucose, fasting insulin, TC, TG, HDL-C, LDL-C | 64.95 ± 8.08 | 65.4 ± 8.8 | 6 months |
|
| |||||||||
| Imamura et al. [17] | Japan | 25 (10/15) | 25 (14/11) | Resveratrol 100 mg, qd | Placebo, qd | HbA1c, fasting blood glucose, fasting insulin, TC, TG, HDL-C, adverse events | 57.4 ± 10.6 | 58.2 ± 10.1 | 3 months |
| Sattarinezhad et al. [18] | Iran | 30 (16/14) | 30 (17/13) | Resveratrol 500 mg, qd + losartan 12.5 mg, qd | Placebo 500 mg, qd + losartan 12.5 mg, qd | HOMA-IR, HbA1c, fasting blood glucose, fasting insulin, adverse events | 56.8 ± 9.7 | 55.7 ± 10.8 | 3 months |
|
| |||||||||
| Khodabandehloo et al. [19] | Iran | 25 (12/13) | 20 (10/10) | Resveratrol 400 mg, bid | Microcellulose (placebo) 400 mg, bid | HOMA-IR, HbA1c, fasting blood glucose, fasting insulin, TC, TG, HDL-C, LDL-C, adverse events | 56.48 ± 6.72 | 61.10 ± 5.61 | 2 months |
|
| |||||||||
| Seyyedebrahimi et al. [30] | Iran | 23 (12/11) | 23 (13/10) | Resveratrol 400 mg, bid | Microcellulose (placebo) 400 mg, bid | HOMA-IR, HbA1c, fasting blood glucose, fasting insulin, TC, TG, HDL-C, LDL-C, MDA, adverse events | 54.96 ± 6.37 | 58.72 ± 6.06 | 2 months |
|
| |||||||||
| Hoseini et al. [31] | Iran | 28 (unknown/unknown) | 28 (unknown/unknown) | Resveratrol 500 mg, qd | Placebo, qd | HOMA-IR, fasting blood glucose, fasting insulin, TG, TC, HDL-C, LDL-C, MDA, TAC, adverse events | 61.0 ± 8.6 | 63.3 ± 10.1 | 1 month |
| Abdollahi et al. [32, 33] | Iran | 35 (15/20) | 36 (16/20)) | Resveratrol 500 mg, bid | Placebo, bid | HOMA-IR, HbA1c, fasting blood glucose, fasting insulin, TG, TC, HDL-C, LDL-C, adverse events | 50.14 ± 7.38 | 50.06 ± 7.69 | 2 months |
|
| |||||||||
| Zhang et al. [34] | China | 48 (24/24) | 48 (23/25) | Resveratrol 300 mg, bid | Blank | HbA1c, fasting blood glucose, fasting insulin, TG, TC, HDL-C, LDL-C | 50.9 ± 9.7 | 52.3 ± 11.2 | 3 months |
|
| |||||||||
| Ying et al. [35] | China | 32 (12/20) | 31 (11/20) | Resveratrol 500 mg, bid | Blank | HbA1c, fasting blood glucose, fasting insulin | 64.94 ± 1.36 | 64.95 ± 1.35 | 2 months |
HOMA-IR: homeostasis model assessment for insulin resistance; TC: total cholesterol; TG: triglyceride; LDL-C: low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol.